Robenacoxib (Onsior) is a non-steroidal compound with strong selectivity for cyclooxygenase-2 and anti-inflammatory activity.

Robenacoxib (2 mg/kg; oral; dogs) by oral (tablet) administration was effective and well tolerated in the control of peri-operative pain and inflammation associated with soft tissue surgery in dogs. Significantly (P = 0.019) more dogs administered Robenacoxib were considered treatment successes (89 of 116, 76.72%) compared to dogs given a placebo (74 of 115, 64.35%). The percentage of treatment failure was therefore 23.28% in the Robenacoxib and 35.65% in the placebo group. The least squares mean total pain scores were significantly different between groups and in favor of Robenacoxib at 3 and 5 hours (P < 0.05) and 8 hours post-extubation (P < 0.01). Pain at the surgery sites (response to touch) was also significantly improved at 3, 5, and 8 hours post-extubation in dogs receiving Robenacoxib versus placebo (P < 0.01). In addition, a significant overall improvement in posture/activity was revealed with Robenacoxib having lower scores versus placebo (P < 0.01). No significant differences between the Robenacoxib and placebo groups in the frequency of reported adverse events were observed.[2]

DMSO: 45 mg/mL (137.5 mM), Sonication is recommended.